Onpattro is generally utilized as a long-term treatment for adults experiencing polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. The treatment plays a role in managing the progressive nature of this serious condition, supporting the long-term management of the condition, and is relevant in contexts marked by increased discomfort or tension. This type of therapeutic approach is commonly used across conditions presenting with acute episodes.

The medication is used for managing symptom clusters that result from nerve damage, specifically addressing sensory deficits (numbness, tingling, burning pain), motor function issues (muscle weakness), and challenging manifestations of autonomic dysfunction (dizziness, digestive problems). The medication is applied in addressing progressive functional impairment in clinical settings, and is used in conditions where functional stability becomes affected. This provides support that helps ease the overall symptom burden, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Polyneuropathy Symptoms The medication supports patients during difficult episodes by easing distress, contributes to easing the overall symptom load, and is relevant for easing symptoms that interfere with daily comfort.

Onpattro (patisiran) is officially approved for use in adult patients (18 years of age and older) diagnosed with hereditary transthyretin-mediated (hATTR) amyloidosis polyneuropathy. The medicine is formally contraindicated in patients with a history of severe hypersensitivity (such as anaphylaxis) to patisiran or to any of its inactive components (excipients).

Eligibility Restrictions and Special Populations

Official regulatory documents define specific limitations for other patient groups:

Population Group	Regulatory Status	Limitation/Condition
Pediatric Patients	Use Not Established	Safety and efficacy have not been established in those under 18 years of age.
Organ Impairment	Use Not Recommended	Not established in moderate or severe hepatic impairment or severe renal impairment/ESRD.
Pregnancy	Use Not Recommended	Requires effective contraception and management of Vitamin A levels due to documented risk.
Older Adults	No Restriction	No dose adjustment is required for patients 65 years of age and older.

Eligibility is also conditioned on the requirement for patients to receive mandated premedications before each infusion to mitigate the risk of infusion-related reactions.

Onpattro (patisiran) has a distinct interaction profile primarily defined by its pharmacodynamic effect on Vitamin A levels, rather than conventional drug-drug interactions involving metabolic enzymes.

Type of Interaction	Details and Management
Reduced Serum Vitamin A	Treatment reduces serum transthyretin (TTR) protein, which is a carrier for retinol binding protein. This results in decreased serum vitamin A (retinol) levels.
Vitamin A Supplementation	Patients must take a daily oral vitamin A supplement at the Recommended Daily Allowance (RDA) throughout treatment. Higher doses should not be used, as serum levels do not reflect total body stores. Ocular symptoms suggestive of deficiency (e.g., night blindness) require ophthalmological referral.
Drug-Drug Interactions	Formal clinical interaction studies have not been performed. Onpattro is generally not expected to cause or be affected by inhibitors or inducers of Cytochrome P450 (CYP) enzymes, a major pathway for drug metabolism.
Premedications	To reduce the risk of infusion-related reactions, patients receive a corticosteroid, acetaminophen, and H1 and H2 blockers prior to each infusion. These agents are considered procedural rather than traditional interacting medicines that affect Onpattro's action.

Gene Silencing via RNA Interference (RNAi)

The mechanism of Patisiran is initiated at the cellular level when its small interfering RNA (siRNA) component utilizes the cell's natural RNA-induced Silencing Complex (RISC) to seek out and bind to the transthyretin (TTR) messenger RNA (mRNA) within liver cells. This mechanism engages a precise, post-transcriptional process that leads to the physical cleavage and degradation of the TTR mRNA.

---

⬇️ Halting TTR Protein Synthesis and Systemic Reduction

The destruction of the TTR mRNA template effectively suppresses the synthesis of TTR protein in the liver, its primary production site. The resulting physiological consequence is a reduction in the concentration of TTR protein—both the variant and wild-type forms—released into the circulation. This systemic reduction influences the availability of TTR protein for subsequent aggregation steps.

---

Interruption of Amyloid Cascade

By reducing the synthesis of the TTR protein, the mechanism directly limits the material available for protein misfolding and subsequent aggregation into new amyloid fibrils. This action limits the accumulation of newly synthesized TTR protein, influencing the progression of TTR deposition. A known systemic consequence of TTR reduction is an indirect decrease in circulating Vitamin A (retinol) levels, as TTR is a transport protein for this complex.

The administration of Onpattro (patisiran) is strictly governed by detailed protocols to ensure proper use of this specialized medicine. The product is supplied as a concentrate for solution for infusion and must be administered solely via the intravenous (IV) route by a healthcare professional.

---

Administration Scope

Property	Official Instruction
Route of administration	Intravenous (IV) infusion only.
Dosing schedule	Dose is calculated based on actual body weight. For patients under 100 kg, the dose is 0.3 mg/kg. For patients 100 kg or greater, a fixed dose of 30 mg is used.
Frequency	Administered once every three weeks as a long-term treatment plan.
Preparation requirements	The concentrate must be aseptically diluted and filtered before use. It must not be shaken or mixed with other medicines.
Age-group rules	No dose adjustment is specified for patients 65 years and older or those with mild or moderate renal or hepatic impairment. The medicine is not approved for pediatric use.
Special procedural conditions	Mandatory premedication is required approximately 60 minutes prior to every infusion. The infusion itself lasts about 80 minutes. Patients are also required to take a daily oral Vitamin A supplement (approx. 2,500 IU) during treatment.

---

Connection to the Overall Use Protocol

The administration protocol for Onpattro is defined by its necessity for clinical supervision, precise weight-based dosage, and a fixed, three-week dosing interval. This structure mandates specialized handling, including pre-infusion protocols and strict adherence to the infusion time, ensuring delivery is consistent with recognized standards.

Research Evidence / Overview of Studies for Onpattro (Patisiran)

Evidence for Use in hATTR Amyloidosis Polyneuropathy

Research for Onpattro was evaluated in a major clinical trial involving adult participants diagnosed with hereditary transthyretin-mediated (hATTR) amyloidosis who had polyneuropathy. This main study was a short-term, randomized, placebo-controlled Phase 3 trial. Being randomized means participants were assigned by chance to either receive Onpattro or an inactive substance called a placebo. The trial lasted for 18 months and was used in research exploring how symptoms change over time.

Study Design and Measured Outcomes

The study research examined how symptoms and daily functioning evolved in the observed populations. To do this, researchers used in research exploring how symptoms change over time standardized tools to measure the progression of nerve damage, such as the Modified Neurologic Impairment Score +7 (mNIS+7). They also applied in studies examining patient-reported experiences questionnaires like the Norfolk Quality of Life–Diabetic Neuropathy (QoL-DN) scale, which outcomes describing perceived discomfort and how the condition affects daily life. Additionally, studies monitored changes in physical ability using measures like the Rasch-built Overall Disability Scale (R-ODS).

The findings describe patterns observed in the studies over the 18-month duration. Specifically, the research reports the differences in the measurements collected during the study period for the groups receiving the study drug compared to the group receiving placebo. These outcomes reflecting daily functioning or activity level and neurological status were tracked to provide insight into short-term changes. Furthermore, the studies consistently data show patterns related to a significant reduction in the amount of TTR protein measured in the participants' blood.

Long-Term Studies and Follow-up Data

The initial, randomized Phase 3 trial was short-term, lasting 18 months. Following this, many participants chose to enter an Open-Label Extension (OLE) study. In these OLE studies, all participants, including those who had previously received placebo, received Onpattro. The OLE research provides context but not individual predictions by tracking participants for longer periods, with follow-up relevant in evidence describing how symptoms are measured extending up to five years or more.

It is important to understand that OLE studies are not randomized or placebo-controlled; they are designed simply to collect data on sustained outcomes over time. The evidence from these long-term studies contributes to the broader evidence landscape by describing how symptoms evolved in the observed populations over defined time intervals. However, because they lack a control group, long-term effects are not fully established with the same certainty as the initial, short-term randomized study.

Evidence in Special Populations and Subgroups

The main Phase 3 trial carefully selected its participants, meaning results apply only to the populations studied. For instance, the research generally focused on patients with mild-to-moderate polyneuropathy and typically excluded individuals who had advanced heart problems or were already confined to a wheelchair.

Because of this, data for certain groups remain insufficient. Specifically, evidence is limited for patients with very advanced stages of the disease or severe heart involvement. Studies explored how the drug was associated with changes in patients who had evidence of heart involvement at the start of the study, and also examined findings across patients with different TTR gene mutations. However, sample sizes were modest for some of these subgroup analyses, and the evidence data are still emerging for certain populations.

Understanding Study Limitations and Evidence Quality

The research for Onpattro is anchored by the findings of the 18-month placebo-controlled trial. The overall evidence quality varies across studies, with the Phase 3 trial being the most highly controlled study design for the short-term outcomes it measured.

However, key structural limitations must be considered. As mentioned, follow-up durations were limited in the gold-standard randomized trial, making it difficult to draw conclusions about the effects over many years. Furthermore, comparative evidence is lacking because research did not include a direct comparison of Onpattro against other approved hATTR amyloidosis treatments; the main trial involved a comparison only to a placebo. Findings describe group patterns, not personal outcomes, and study results reflect the specific conditions under which they were conducted.

What Remains Uncertain About Onpattro

Despite the available research, several questions remain that require further study. Long-term effects are not fully established for outcomes such as patient survival or the sustained impact on heart function over periods greater than 18 months.

Limited information for long-term outcomes exists for certain patient subgroups, such as those with severe kidney disease. Additionally, the research does not determine whether an individual will respond similarly to the group findings. Finally, although various outcomes related to physical discomfort and daily functioning were studied, the full complexity of how the condition impacts individuals means that evidence highlights what is known — and what is still uncertain — about every aspect of the disease's progression.

Common questions about Onpattro (FAQ)

Q: Can the dose of the pre-medication be reduced over time?

Regulatory documents state that for patients who tolerate their infusions but experience adverse reactions related to the corticosteroid premedication, the dose may be reduced. Official product information describes the process of dose reduction in 2.5 mg increments, down to a minimum dose of 5 mg (dexamethasone or equivalent). Any discussion of changes to premedication is handled by the prescribing healthcare provider.

Q: What are the criteria for a patient to receive the infusion at home?

Home infusion may be considered for patients once official documentation indicates they have tolerated at least three infusions well in the clinical setting. Official recommendations confirm this option must be determined by the treating physician. The home infusion is to be administered by a qualified healthcare professional.

Q: What should a patient do if they miss a scheduled infusion day?

Regulatory information provides guidance regarding adjustments to the schedule for missed doses. If the dose is administered within three days of the scheduled date, the original three-week dosing schedule is maintained. If the dose is administered more than three days late, the three-week dosing schedule is reset to continue from the day the missed dose was administered.

Q: What are the most common symptoms of an Infusion-Related Reaction?

Official product information describes Infusion-Related Reactions (IRRs) as a common safety event. The most common symptoms reported in clinical studies include flushing, back pain, nausea, abdominal pain, headache, and dyspnea (trouble breathing). The risk of these reactions is managed by the mandatory premedication given before the infusion.

Q: Is it true that Infusion-Related Reactions are more likely during the first few infusions?

Yes, evidence indicates that Infusion-Related Reactions (IRRs) are generally more frequent when treatment is initiated. In clinical studies, the majority of patients who experienced an IRR had their first reaction within the first two infusions. The frequency of these reactions was observed to decrease over the course of the treatment period.

Q: What is done to manage an Infusion-Related Reaction if it occurs?

If an Infusion-Related Reaction (IRR) is experienced, the healthcare provider administering the medicine may slow or interrupt the rate of the infusion. The patient may also receive additional medical management for the symptoms. Regulatory protocol describes the condition under which the infusion is completely discontinued in case of a serious or life-threatening reaction.

Q: Are upper respiratory infections, like colds, a common side effect of Onpattro?

Yes, official safety information indicates that upper respiratory tract infection is a Very Common side effect associated with the use of Onpattro. This category includes common ailments like colds and sinus infections, which were reported in more than 10% of patients in clinical studies.

Q: Does Onpattro carry a risk of heart problems, such as heart block?

Official regulatory documents indicate that a specific heart problem known as Atrioventricular (AV) heart block was reported in a small percentage (2.7%) of patients in clinical studies. This involves a problem with the heart’s electrical signals. This information is intended for review with a healthcare provider, especially concerning any existing heart conditions.

Q: What are the symptoms of heart block that patients should be aware of?

Symptoms of heart block are often described as being related to a decrease in the heart's function. These may include feeling dizzy, lightheaded, or fainting (known as syncope). This information is provided to patients for review with their healthcare provider.

Q: What are the common vision or eye problems associated with low vitamin A levels?

Because Onpattro lowers the protein that transports Vitamin A, patients may experience symptoms related to vitamin A deficiency. These ocular symptoms may include reduced night vision or night blindness, persistent dry eyes, eye inflammation, or corneal issues. This is why daily vitamin A supplementation is a regulatory requirement during treatment.

Q: Are there any long-term side effects associated with Onpattro treatment?

The most common and serious side effects observed in the short-term controlled study are known. However, regulatory documents indicate that the long-term effects of Onpattro are not fully established because the primary controlled trial lasted 18 months. Data for sustained outcomes are collected in long-term extension studies.

Q: What does 'peripheral edema' mean, and is it a common side effect?

Peripheral edema is a medical term for swelling, most commonly seen in the lower limbs such as the ankles and feet. Official safety information lists peripheral edema as a Very Common side effect, meaning it occurred in a high percentage of patients in the clinical trials.

Q: Does Onpattro cause issues like back pain, joint pain, or muscle spasms?

Yes, the official list of adverse reactions includes muscle spasms as a Common side effect (reported in 1% to 10% of patients). Joint pain (arthralgia) and back pain are also reported as common symptoms that may be associated with Infusion-Related Reactions.

Q: What should I know about potential interactions with common heart medications?

Formal clinical studies examining drug-drug interactions, particularly with common cardiovascular medications, have not been conducted. However, the product is not expected to be a major cause of interactions involving the main drug metabolism pathways (CYP enzymes).

Q: Does Onpattro interact with any specific foods or common dietary supplements?

Aside from the necessary daily Vitamin A supplement, there are no specific foods or other common dietary supplements that have been officially reported to interact with Onpattro. The information provided is based on regulatory documentation.

Q: Is Onpattro safe for women who are pregnant or planning to conceive?

Official information states that Onpattro should not be used during pregnancy unless the treatment is considered necessary. This is due to the risk of abnormal vitamin A levels harming the unborn child. Official guidance describes the necessity of effective contraception during the course of treatment for women of childbearing potential.

Q: What are the official recommendations for breastfeeding mothers using Onpattro?

It is currently unknown whether the active component of Onpattro passes into human breast milk. Due to the lack of information and potential risk to a breastfed infant, official guidance describes the option to discontinue nursing or discontinue the drug.

Q: Why is the infusion dose calculated based on a patient's body weight?

The recommended dosage for Onpattro is determined by a measurement of 0.3 mg of the drug per kilogram of the patient's actual body weight (for patients under 100 kg). This approach indicates that body weight is the primary factor used by physicians to calculate the specific, individualized dose required for treatment.

Q: What is the definition of extravasation, and why is it a concern during infusion?

Extravasation refers to a situation where the medicine leaks out of the intended vein and into the surrounding tissue at the infusion site. Symptoms of this include pain, a burning sensation, redness, or swelling. The protocol describes the necessity for the infusion to be stopped and the affected area to be clinically managed if this occurs.

Q: What should be done if the Onpattro vials are accidentally frozen?

Official storage instructions state that unopened Onpattro vials should not be frozen and must be kept in a refrigerator. If a vial has been accidentally frozen, the regulatory guidance requires that it be discarded and not used for infusion.

Q: What is the process for monitoring the effectiveness of Onpattro over time?

Regulatory documents require ongoing monitoring of certain biological factors, specifically liver function tests (transaminases) and serum Vitamin A levels. Effectiveness monitoring is a clinical decision based on physical examination and patient-reported scores.

Q: What kind of specialist typically prescribes and manages Onpattro treatment?

Official product information indicates that treatment with Onpattro should be started and supervised by a physician who has experience in the treatment of patients with amyloidosis. This ensures specialized care and monitoring for the disease.

Q: Are there any specific safety warnings for patients with kidney disease?

Official information indicates that no dose adjustment is necessary for patients who have mild or moderate renal impairment (kidney disease). However, the safety and efficacy of the drug have not been established in patients with severe renal impairment or end-stage renal disease.

Q: What is the potential impact of Onpattro on the body's immune system?

Official safety data mentions that Infusion-Related Reactions are related to the body's response, often involving hypersensitivity. Additionally, anti-drug antibody formation (where the body's immune system develops antibodies to the drug) was reported in a small percentage of patients (1% to 10%) in clinical trials.

Q: What are the potential signs of a serious allergic reaction to Onpattro?

Signs of a serious allergic reaction, which is a life-threatening event requiring immediate medical attention, may include swelling of the face, lips, tongue, or throat (which can cause difficulty breathing), hives, or significant difficulty breathing. These are distinct from the common infusion-related reactions.

Onpattro (patisiran) vials should be stored in a refrigerator between 2 C and 8 C (36 F and 46 F). Do not freeze the vials; if the medicine has been frozen, it must be discarded.

If refrigeration is not possible, unopened vials can be stored at room temperature (up to 25 C or 77 F) for a single period of up to 14 days. Once the drug is diluted for infusion, the solution should ideally be administered immediately. If necessary, the diluted solution can be stored in the infusion bag at room temperature (up to 30 C or 86 F) for up to 16 hours, including the time required for the infusion.

Always keep this medicine out of the sight and reach of children and do not use it past the expiration date on the carton. Disposal of unused or expired medicine, along with any related supplies, must be performed by a healthcare professional in accordance with local environmental requirements, and should not be placed in household waste or wastewater.